

cancer.

T cell targeted immunotherapy







indicated markers among myeloid subsets as defined in (A).

Cancer immunotherapy via myeloid signaling pathway co-activation

Max M. Wattenberg¹; Heather Coho¹; Veronica M. Herrera¹; Kathleen Graham¹; Mingen Liu¹; Shaanti Choi-Bose¹; Stacy K. Thomas¹; Hana Choi¹; Yan Li¹; Lauren Melendez¹; Michael Gianonne¹; Nandita Bose²; Gregory L. Beatty¹

> ¹Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA ²HiberCell Inc. Roseville, MN





CA076931-21 (to M.M.W.), R01-CA197916 (to G.L.B.), R01-CA245323 (to G.L.B.), and U01 CA224193 (to G.L.B.), the Damon Runyon Physician Scientist Training Award (to M.M.W.) and a grant from HiberCell.

